¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ
¼¶±ð: ³õ¼¶²©ÓÑ
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-04-19   

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æ×¨Òµ£º e' `xU  
Qoj}]jve  
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ 4zF|}aiQ  
<z>K{:+>  
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) ")q{>tV  
UL/|!(s  
1. ICAM-1 n&. bs7N2  
Z66b>.<8  
2. interleukin 12(IL-12) JJvf!]  
I6]|dA3G  
3. tumor infiltrating lymphocyte /S]W< 8d  
`.# l_-U{  
4. TCR/CD3 complex 2p(M`@  
w"CcWng1  
5. hematopoietin receptor family CfMq?.4%E}  
qAH@)}  
6. individual idiotype(IdI) ;Yrg4/Ipa  
H=vrF-#  
7. integrin k'N `5M)  
)x.}B4z  
8. colony-stimulatory factor (CSF) (~oUd 4  
/&=E=S6  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© d:0RDK-}s  
Y[gj2vNe4g  
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? bz_Zk  
V *=To  
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ tRYMK+  
<@n/[ +3  
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷Óᣠ88}c+V+N!  
XM3N>OR.  
4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØÏµ¡£ OiX>^_iDt  
lhTjG,U=  
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) s+>""yi  
n6; jIf|  
1. ÊÔÊö¸ÉÈÅËØµÄ·ÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌØµã¡£Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËØ¼ì²âµÄ·½·¨ºÍÔ­Àí¡£ X 'Q$v~/  
\pZ,gF;y  
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) o)'T#uK  
\`o+Le+%  
3. immunoglobulin superfamily (IgSF) oK@!yYv  
[AQ6ads)  
4. selectin aQwcPy|1R  
>/1N#S#9  
5. anti-idiotypic antibody (¦ÁId) xh[Mmq/R  
*. l,_68  
6. major histocompatibility complex(MHC) [o <R#f`  
T5NO}bz  
7. immunotolerance ~WU _u,:  
,Cj1S7GFR  
8. biological reponse modifier(BRM) 2}>jq8Y47  
mJRvC%  
9. immune reponse gene (Ir gene) +:?-Xd:p  
BKfcK>%g  
10. reshaped antibody (or reconstituted antibody) R!;tF|]  
_KC)f'Cx  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© \v{tK;  
d*Dq=.F(  
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ bKj#HHy\I  
r^-3( 77n  
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? ct=|y(_  
zg2A$Fd[j  
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ E{sTxO I$  
L B1 ui  
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? N,V %/O{Y  
PmyS6a@  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ {co(w 7  
"12.Bi.O"[  
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? kc^ Q ?-?  
I \zM\^S>]  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ %50}oD@  
X+;Ivx  
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ KL,=Z&.<=  
Mz# &"WjF  
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨? -q|K\>tgU  
"{105&c\  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ 6|wi Zw  
eWS[|' dl  
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: xCF k1%qf  
=:n>yZ3T  
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: vt<r_&+ pJ  
8PB(<|}u  
ÃâÒßѧ >J^bs &j  
ZQ9!k* ^  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© ne] |\]  
v]\io#   
1. CD8 CdgZq\  
dqO!p6  
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) }UJS*m R  
>;kCcfS3ct  
3. immunoglobulin fold(Ig fold) $7eO33Bm  
BlUl5mP}>  
4. cadherin (Ca-dependent cell adhesion moleculers) a5ZU"6Hi  
l? v`kAMR  
5. idiotype-anti-idiotypic antibody immune network theory QEK,mc3  
n0g,r/  
6. HLA class II antigen 5_Yl!=  
< .&t'W  
7. complementarity-determining region (CDR) 2-5AKm@K  
. [DCL  
8. perforin(or pore-forming protein ,PFP) $~vy,^  
ON#\W>MK?  
9. high affinity IL-2 receptor P5/K?I~/So  
#A<|&#hh  
10. artificial active immunization yL/EIN  
5Nc~cD%0tK  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© RaT(^b(  
`3+yu' Q'  
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦Óᣠsu6x okt  
Li~(kw3  
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 It'hmwu#  
u4TU"r("A  
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ amq]&.M  
[^xLK  
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô­¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ 4DI.R K9  
*0]E4]ZO  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£ UMR0S5`}  
^2E\{$J  
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? ^$qr6+  
*A C){M  
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ vmdu9"H  
@Ee{ GH^-  
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ G)5w_^&%  
)6U&^9=  
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ K] ;`  
%!%G\nv  
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ [kwVxaI  
_mVq9nBEf  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© *,q W9z  
D?;8bI%"  
1. immunoglobulin gene rearrangement SXX6EIJr|  
\| qr&(PG  
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors) 1L722I @  
F FHk0!3  
3. flow cytometry(FCM) d]Y-^&]{]  
E fA*w/y  
4. carrier effect 0}:- t^P  
r #H(kJu,  
5. positive selection of T lymphocytes in thymus |"V]$s$ c  
2<&lrsh  
6. mouse TH1(Th1) and TH2(Th2) subsets ]pUf[^4  
9MfBsp}c  
7. perforin (pore-forming protein ,PFP) qMy>: ,)Z  
AIZs^ `_  
8. ADCC(antibody-dependent cell-mediated cytotoxicity) ",wv*z)_>  
&8VB{S>r  
9. SH-2(src-homology region 2) [I/f(GK  
Y 1 e>P  
10. Ab2¦Â (internal image) k.Tu#7  
yEYlQ=[#  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© r\6 "mU  
Jpi\n- d!  
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? )$18a  
1J8okBhZ  
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? z}I4m  
K$>C*?R  
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦ÓᣠRw4"co6  
Vc}#Ok  
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ hoy+J/  
IyTL|W6  
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦ÓᣠJw%0t'0Zi  
]{- >/.oB  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) 7^Y"K  
u,<#z0R|;$  
ÃâÒßѧרҵ£º c^^[~YW j  
>;@ _TAF  
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ 1mT3$Z  
5GD6%{\O  
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? Ns.b8Y  
r)$(>/[$  
´«È¾²¡Ñ§×¨Òµ£º Ktrqrl^IJ  
_jmkAmeu  
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ jkd'2  
iN\D`9e  
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ -)%l{@Mr  
C[h"w'A2  
Ïû»¯×¨Òµ£º  M1>< K:  
KCR6@{@  
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£ <ptZY.8N  
>5Vv6_CI0?  
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? > %5<fK2  
Q[t|+RNKv2  
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ (UW V#AR  
E"p;  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© d(u"^NH;  
=FXO1UZ!  
1. Fas(CD95)/FasL 1-`Il]@?8  
p8CDFLuV  
2. common chain of cytokine receptor ,tt]C~\u  
n&V\s0  
3 . TCR/CD3 complex X 4\  
`9IG/ /  
4. negaive selection of thymocytes }GV5':W@WG  
Ae,P&(  
5. artificial active immune xY] Y  
7[=MgnmuC  
6. anti-idiotypic g"pjWj)?  
zo!e<>o  
7. IgSF l42 3+vo  
_ISIq3A?  
8. Integrin >)E{Hs  
cj=6_k  
9. chemokine VJp; XM  
NJ 6* 7Cd  
10. B7/CD28 z"[}Sk  
Rn(6Fk?   
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© m-%.LDqM  
F#<$yUf%  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£ rd#O ]   
ZboY]1L[j  
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ C"X; ,F<  
X:3W9`s )*  
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£  nIWZo ~  
aJAQ G  
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ _VvXE572  
$G $147z  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ luPj'd?  
5;:P^[cH9  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ y9/x:n&]  
/b ]Yya#  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© p`oSI}ZwB  
f`^\v  
1. B7/CD28 J ~"h&>T  
_T8o]  
2. Th1 subset =zetZJg  
:4HZ >!i  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© liU/O:Ap  
h#E ksX  
4. antibody affinity maturation n91@{U)QJ3  
x{|`q9V~ N  
5. AP-1 CcDi65s  
<"}Gvi  
6. single chain variable fragment£¨ScFv£© "3\C;B6I  
6Z:swgi6&  
7. NK cell receptor 2{`[<w  
8Ev,9  
8. Zinkernagel-Doherty phenomenon rB<za I\V  
:t'*fHi~  
9. Ig fold XZ3)gYQi  
 }}cS-p  
10. CD40/CD40L |IgH0 zZ  
@ff83Bg  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© 5Vj t!%?r  
Fh3>y2 `/  
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ mv0JD(  
X / {;  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ ,[j'OyR  
REaU=-m-  
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿  >bo_  
I8%2tLVY  
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ 8rXQK|A  
P_:~!+W,  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ kM>Bk \  
"'8^OZR  
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ >w}5\ 4j  
}CoR$K   
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ ^kElb;d  
(oKrIm  
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£© T]#S=]G  
R54wNm @  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© [RqL0EP  
M y v yp  
1.Co-stimulators (or co-stimulating molecules) /&`sB|  
ioZ{2kK  
2.NK-kB x'c%w:  
(H/2{##  
3.Immunoglobulin superfamily *G6Py,- !f  
lO=Nw+'$S  
4.antigen-presenting cell (APC) LMF@-j%  
KO~_  
5.death domain ?aMV{H*Q*  
)Td;2  
6.CCR and CXCR Tf|?j=f  
.d4L@{V  
7.Lectin (or mitogen) %+=y!  
m#^ua^JV  
8.Clusters of differentiation, CD) 91Fx0(  
^~iFG+g5  
9.B7 family 0pC}+ +  
i xf~3Y8  
10.Cytotoxic T lymphocyte, CTL) ^uDNArDmj5  
b%TS37`^[  
11.IL-15 and IL-15 receptor (IL-15R) EGY'a*]cU  
24}?GO  
12.MHC restriction 3Y L  
-Tzp;o  
13.Affinity-chromatography l$1z%|I  
QXQ'QEG  
14.Cyctosprin A, CsA n' XvPV|  
&7}\mnhB  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) 8@}R_GZc  
`Wes!>Vh!  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© u(Y! _  
%X--`91|u  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 >I~$h,  
8Moe8X#3  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ *tWZ.I<<  
DaA9fJ7a   
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ rzR=% >  
TjU g8k  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© AM[#AZv  
TL29{'4V  
ÃâÒßѧרҵ£º aB=&XGV9  
];3]/b)&  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ ,n}h_ct  
4TP AD)C  
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ JGJy_.C  
NSsLuM=.  
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ ^`HP&V  
csEF^T-  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) |8|_^`  
3pV^Oe^9  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) (i 3=XfZ!C  
2;v1YKY  
1. ADCC(antibody dependent cell-mediated cytotoxicity) ' )0eB:  
VV$$t;R/  
2. »·æß¾úËØ(cyclosporin) w;p: 4`  
K [.*8  
3. KIR(killer cell inhibitory receptor) &f;<[_QI=  
%6%QE'D  
4. HLDA(human leucocyte differentiation antigen) ::lD7@Wg  
Z [aKic  
5. Interleukin 18(IL-18) BDO]-y  
iE}Lw&x  
6. ÕûºÏËØ(integrin) &>YdX$8x  
B5pWSS  
7. Fas/FasL >l$qE  
5, j&-{ 0W  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) BM }{};p6  
bMrR  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) ;ATn&  
/Tc I  
10. Th1/Th2 v)!C Dpw  
z5UY0>+VdS  
11. »ùÒòÒßÃç(DNAÒßÃç) ij|+MX  
8 Q*477=I  
12. chemokines and chemokine receptor Jq1^}1 P  
&y~~Z [.F,  
13. ÃâÒßÄÍÊÜ Z2t r?]  
xV}ybRKV  
14. ¹²´Ì¼¤·Ö×Ó ;LhNz()b  
%z_L}L  
15. ËÀÍö½á¹¹Óò(death domain) {0ozpE*(  
RPh8n4&("  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) O\5q_>]  
).8i*Ys,:  
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? )2YZ [~3  
Nm;V9*5  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦ÓᣠAgU 7U/yk  
MB#KLTwnT  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î $1ZF kw  
* SHQ[L4{  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ /q eSR3WC  
%CaUC'  
£¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå  M .J  
g 218%i  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ }aJK^>^>A  
;xl_9Ht/  
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) |-'.\)7:  
w?db~"T  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ < Ky6|&!  
CNRiK;nQ  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ N:yyDeGyW  
ZR|cZH1}C  
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
Ãâ·Ñ¿¼²©ÍøÍøÖ·ÊÇʲô? ÕýÈ·´ð°¸:freekaobo.com
°´"Ctrl+Enter"Ö±½ÓÌá½»